Nivolumab Maintained QOL in Advanced Squamous Cell Head and Neck Cancer

Patients with recurrent or metastatic squamous cell carcinoma of the head and neck treated with the checkpoint inhibitor nivolumab were able to maintain baseline levels of quality of life.

Source: CancerNetwork - June 28, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Head & Neck Cancer News Source Type: news